BioSpace News Archive

The company announced positive topline results in its Phase III study of Xpovio (selinexor) in patients with advanced unresectable dedifferentiated liposarcoma, which sets up potential approval in this indication.

At the University of Southern California, Dr. Eun Ji Chung and Dr. Mitchell Gross are tackling cancer at the nanoscale.

Vifor Fresenius Medical Care Renal Pharma Ltd. and ChemoCentryx, Inc., announced that the European Medicines Agency accepted to review the Marketing Authorization Application for avacopan for the treatment of patients with ANCA-associated vasculitis and microscopic polyangiitis ), a group of rare and severe autoimmune diseases with high need for targeted therapies.

Itamar Medical Ltd., a medical technology company focused on the development and commercialization of non-invasive medical devices and solutions to aid in the diagnosis of respiratory sleep disorders, announced that it will report its unaudited financial results for the third quarter 2020 before the U.S. market opens on Tuesday, November 17, 2020.

For the first time, Canadians will have access to at-home HIV self test kits. bioLytical Laboratories, a world leader in rapid infectious disease tests, announced that it has received Health Canada Licence to produce and sell its highly accurate, 1-minute INSTI® HIV Self Tests in Canada.

QYNAPSE SAS, a medical technology company, will present results on QyPredict®, an AI prediction technology for patient selection in Alzheimer’s clinical trials, at the 13th Clinical Trials on Alzheimer’s Disease Conference.

Viseon, Inc., a leader in minimally invasive spine visualization technologies, announced use of its new miniature camera system, MaxView™, for single position prone XLIF® surgery.

InspireMD, Inc., the developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by carotid artery disease, announces the appointment of Andrea Tommasoli as senior vice president of global sales and marketing.

The global advanced wound care management market is anticipated to experience substantial growth owing to several research and development based activities taking place through intensive efforts made by well-established competitive players.

PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on developing its clinically-validated and patent-protected PLxGuard™ delivery system to provide more effective and safer products, VAZALORE™ 325 mg and VAZALORE™ 81 mg (referred to together as “VAZALORE”™), announced today that the Company will release its 2020 third quarter financial results on Friday, November 13, 2020